Jean-Charles Soria, SVP and Oncology Therapeutic Area Head of Amgen, shared a post on LinkedIn:
“MSI-H = hallmark of mismatch repair (MMR) deficiency.
Prevalence: ~30% endometrial, ~10% CRC, ~8% gastric.
But not all MSI-H/dMMR tumors are alike:
1.MSH2/MSH6 loss → ↑ TMB, better ICI response
2.PTEN/AKT1 mutations → ICI resistance
Checkpoint blockade is now 1L in CRC and endometrial.”
Title: Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
Journal: Nature Reviews Clinical Oncology
Authors: Margherita Ambrosini, Paolo Manca, Vincenzo Nasca, Carolina Sciortino, Filippo Ghelardi, Jenny F. Seligmann, Julien Taieb, Filippo Pietrantonio
More posts featuring Jean-Charles Soria on OncoDaily.